following a full submission:
rucaparib (Rubraca®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
In a phase III study, maintenance treatment with rucaparib significantly improved investigator-assessed progression-free survival, compared with placebo, in patients with advanced ovarian cancer who were in response to first-line platinum-based chemotherapy.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Medicine details
- Medicine name:
- rucaparib (Rubraca)
- SMC ID:
- SMC2799
- Indication:
As monotherapy for the maintenance treatment of adult patients with
advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.- Pharmaceutical company
- pharmaand GmbH (pharma&)
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 September 2025